Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
Open Access
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 26 (4) , 986-995
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R21NS101150, R21NS089802)
- James S. McDonnell Foundation
This publication has 57 references indexed in Scilit:
- New development in CAR-T cell therapyJournal of Hematology & Oncology, 2017
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyNew England Journal of Medicine, 2016
- Antitumour actions of interferons: implications for cancer therapyNature Reviews Cancer, 2016
- IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in miceOncotarget, 2015
- IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer MetastasisCancer Research, 2015
- Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine ReceptorMolecular Therapy, 2014
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- T Cells Redirected to EphA2 for the Immunotherapy of GlioblastomaMolecular Therapy, 2013
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts SurvivalClinical Cancer Research, 2012
- Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.Journal of Experimental Medicine, 1991